Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of Haemonetics Corporation's 2024 Annual Meeting of Shareholders held on July 25, 2024. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity figures are not provided in this document.
Material Changes
No material financial changes are reported in this filing. The document focuses exclusively on the ratification of shareholder votes.
Outlook, Risks, and Management Commentary
The filing contains no management commentary on future outlook, risks, contingencies, or unusual items. It strictly reports the procedural results of the annual meeting.
Key Facts for Investors
- Quorum Achieved: 48,912,250 shares were represented at the meeting, constituting 95.99% of the 50,953,098 shares entitled to vote.
- Director Elections: All nine nominees (Christopher A. Simon, Robert E. Abernathy, Diane M. Bryant, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy, and Ellen M. Zane) were elected to one-year terms expiring in 2025.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 46,230,466 votes "For" and 1,460,004 votes "Against."
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 30, 2024.